Business
4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights
Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating preliminary evidence of clinical activityAdvanced two additional programs into clinical development: R100 vector-based 4D-150 for wet AMD, and A101 vector-based 4D-710 for cystic fibrosisInitiated expansion of our GMP manufacturing facilities for potential commercial-scale clinical manufacturing capabilities$315 million in cash, cash equivalents and investments at end of 2021 expected to fund operations into the second half of 2024 EMERYVILLE, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced full year 2021 financial results and provided operational highlights. “In our first full year as a publicly traded company, 4DMT continued to advance our diverse pipeline of five clinical-stage product candidates in three distinct therapeutic areas for both rare and large market diseases, all of which utilize targeted and evolved vectors from our Therapeutic Vector Evolution platform. With the release of promising initial clinical data on three programs and the IND clearances of two additional programs, we delivered on our goals and guidance for 2021,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “We also continued to build a strong clinical and scientific team that is focused not only on our clinical programs but also on continuing to advance our Therapeutic Vector Evolution platform and preclinical product pipeline. We’ve entered 2022 with a strong cash runway into the second half of 2024. By harnessing the power of our Therapeutic Vector Evolution and GMP manufacturing platforms, 4DMT has built a robust product development engine to continue our mission to unlock the full potential of genetic medicines for countless patients.” 2021 Operational Highlights Provided clinical data updates on three programs, including first clinical activity data from two 4DMT targeted and evolved vectors: C102 for systemic low dose cardiovascular delivery and R100 for routine intravitreal delivery. Presented Phase 1/2 clinical data on 4D-310 for Fabry disease that demonstrated mean AGA en...